- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01574742
Open Study Assessing the Feasibility of Minocycline in Patients With Unipolar Depression
A Single Center, Open Label Study Assessing the Feasibility, Safety and Therapeutic Effect of Minocycline in Adult Patients With Diagnosis of Unipolar Depression.
A single center, open label study assessing the feasibility, safety and therapeutic effect of Minocycline in adult patients with diagnosis of unipolar depression. Up to 30 patients diagnosed with unipolar depression that are in a current depressive episode. The patients will be of all racial, ethnic and gender categories, ranging from 18 to 68 years of age, and have HDRS-21≥20. All subjects will continue to take their treatment with antidepressant medications for the duration of the study. All subjects are prescribed minocycline 200 mg/day orally (2X100 mg) for the first 3 days. than, all subjects are prescribed minocycline 400 mg/day orally (2X200 mg) from day 4 until termination visit (day 35). The primary objective of this study is to assess the therapeutic effect of Minocycline in unipolar depression.
The secondary objectives of this study are to assess the therapeutic effect, the feasibility and safety of Minocycline in unipolar depression.
Visão geral do estudo
Tipo de estudo
Inscrição (Antecipado)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
-
Hod-HaSharon, Israel
- Recrutamento
- Shalvata Medical Health Center
-
Contato:
- Yechiel Levkovitz, MD, PhD
- Número de telefone: 00-972-9-7478644
- E-mail: ylevk@clalit.org.il
-
Investigador principal:
- Yechiel Levkovitz, MD,PhD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Outpatients and inpatients
- Men and women 18-68 years of age.
- Primary DSM-IV diagnosis of Depression, single or recurrent episode confirmed by the Structured Clinical Interview for the DSM-IV (SCID-IV), with the additional requirements of a current episode ≥4 weeks and CGI-S ≥4.
- Total HDRS-21 ≥20 and Item 1 score ≥2 at the screening visit.
- The patient did not respond to at least one antidepressant medication given for an accepted dose and duration.
- Capable and willing to provide informed consent
Able to adhere to the treatment schedule.
-
Exclusion Criteria:
- Depression secondary to a general medical condition.
- History of substance abuse or dependence within the past 6 month (except opioids, nicotine and caffeine).
- All antidepressant medications, must have been in stable dosage for at least 3 weeks prior to entry into the study, with no anticipation of change over the duration of the study.
- Use of any medication(s) listed on the Excluded medication list within the time that mansion for each medication on the list.
- Any psychotic disorder (lifetime), including schizoaffective disorder, or major depression with psychotic features • Bipolar disorder • Eating disorder
- Subjects who were taking a known contraindication to minocycline treatment.
- Subjects who had received treatment with minocycline or β-lactam antibiotics in the preceding half year before study entry.
- Present suicidal risk as assessed by the investigator or significant suicide risk based on HDRS-21 item 3 score of 3 or 4 or a history of attempted suicide in the last 6 month
- Known or suspected pregnancy or women of childbearing potential and not using a medically accepted form of contraception when engaging in sexual intercourse.(if using oral contraceptives, during the minocycline treatment, subject should use an additional contraceptives), or women who are breastfeeding
Patients with severe hepatic or renal insufficiency.
-
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Minocycline
Minocycline 200 mg/day (2X100 mg) from day 1 to day 3 and Minocycline 400 mg/day (2X200mg) form day 4 until termination visit (day 35)
|
Minocycline 200 mg/day (2X100 mg) from day 1 to day 3 and Minocycline 400 mg/day (2X200mg) form day 4 until termination visit (day 35)
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Depression symptoms
Prazo: from baseline (day 1) to termination (day 35)
|
The change in Scale for Depression (HDRS-21) score from baseline to the end of the study (visit 4 - day 35) where response is defined as ≤50% reduction in HDRS-21 score from baseline.
|
from baseline (day 1) to termination (day 35)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Depression symptoms - CGI
Prazo: from baseline (day 1) untill termination visit (day 35)
|
The change in Clinical Global Impression Scale (CGI) from baseline to the end of the study.
|
from baseline (day 1) untill termination visit (day 35)
|
depression symptoms - (QIDS-SR)
Prazo: from baseline (day 1) untill termination visit (day 35)
|
The change in Quick Inventory of Depressive Symptology -self report (QIDS-SR) from baseline to the end of the study.
|
from baseline (day 1) untill termination visit (day 35)
|
depression symptoms - HDRS-21
Prazo: from baseline (day 1) untill termination visit (day 35)
|
Remission rates after 5 weeks of Minocycline treatment, where remission is defined as HDRS-21 score <10.
|
from baseline (day 1) untill termination visit (day 35)
|
Safety
Prazo: frpm baseline (day 1) untill the termination visit (day 35)
|
Safety Evaluation: Tolerability of Minocycline as defined by maintained subject baseline, pre-treatment, physical and neurological examinations and lack of significant increase in suicide ideation measured by:
|
frpm baseline (day 1) untill the termination visit (day 35)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Yechiel Levkovitz, MD, PhD, Shalvata Medical Health Center
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 0007-12-SHA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Depressão Unipolar
-
University Hospital, MontpellierAssistance Publique - Hôpitaux de Paris; University Hospital, Clermont-Ferrand; Centre Hospitalier Universitaire de Nice e outros colaboradoresRecrutamentoPacientes ambulatoriais com depressão unipolar | Gravidade leve | Sem Características PsicóticasFrança
-
University GhentUniversity Hospital, GhentConcluído
-
Kyoto UniversityNational Center of Neurology and Psychiatry, JapanConcluídoEpisódio Depressivo Maior UnipolarJapão
-
Centre Hospitalier Universitaire de BesanconDesconhecido
-
Brown UniversityProvidence VA Medical CenterDesconhecidoDepressão UnipolarEstados Unidos
-
Brown UniversityConcluídoMild-moderate Unipolar Depression; Persistent Negative AffectEstados Unidos
-
Jay FournierAinda não está recrutandoDepressão Unipolar
-
Rebecca PriceConcluído
-
University Hospital, MontpellierRescindido
-
University of OxfordNational Institute for Health Research, United KingdomAinda não está recrutando